Comparing single-fraction palliative radiotherapy to standard multi-fraction radiation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate whether a single fraction of escalated dose palliative radiotherapy can provide longer-lasting benefits compared to the standard multi-fraction approach for patients with metastatic cancer. The primary goal is to assess the percentage of patients who experience significant symptom relief and do not redevelop symptoms within 12 months post-treatment. The study focuses on patients who are typically unwell due to advanced disease and aims to optimize treatment by minimizing the number of sessions while maximizing quality of life. By exploring hypofractionated radiation, the study seeks to enhance local control and reduce the need for retreatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Metastatic cancer
* Recommended for 5-10 fractions palliative radiation
* Patients with spinal cord compression are eligible for enrolment

Exclusion Criteria:

* Unwilling or unable to give informed consent
* Patients who are recommended for single fraction palliative radiation

Where it's running

• Royal North Shore Hospital
  Saint Leonards, New South Wales, Australia Recruiting

Study contacts

• Principal investigator: Thomas Eade — Northern Sydney Cancer Centre, Royal North Shore Hospital
• Study coordinator: Carol Kwong, RN
• Email: carolyn.kwong@health.nsw.gov.au
• Phone: +61294631339

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Lattice radiation therapy for large unresectable tumors

  This trial will try Lattice Radiation Therapy given in five alternate-day sessions with a focused boost to control large, unresectable tumors in adults needing palliative radiotherapy.

  Recruiting Phase 2 Azienda USL Reggio Emilia - IRCCS · Reggio Emilia, Italy · NCT07000162

• Hybrid Arc (HART) palliative radiation for metastatic solid tumors

  This trial tests whether Hybrid Arc Radiation Therapy (HART) lowers acute gastrointestinal side effects in adults with metastatic solid tumors who need palliative radiotherapy.

  Recruiting Phase 2 University of Vermont Medical Center · Burlington, Vermont · NCT06778408

• PSMA PET/CT for GBM patients on bevacizumab

  This study tests PSMA PET/CT scans in adults with IDH-wildtype glioblastoma who are receiving bevacizumab to see how PSMA expression relates to VEGF in their tumors.

  Recruiting Royal North Shore Hospital · Saint Leonards, New South Wales · NCT07052877

• Adaptive radiotherapy for pelvic cancers

  This trial will test whether radiation therapist–led adaptive radiotherapy, including smaller treatment margins, can reduce side effects for adults getting curative or adjuvant pelvic radiotherapy.

  Recruiting Royal North Shore Hospital · St Leonards, New South Wales · NCT06650033

• Adaptive radiation for prostate cancer

  This study tests whether daily adaptive radiotherapy led by radiation therapists, with the option to use smaller treatment margins, can reduce side effects for men having prostate radiotherapy.

  Recruiting Royal North Shore Hospital · St Leonards, New South Wales · NCT06547398

• AI-assisted contouring for breast cancer radiation treatment

  This study is testing if using AI to help outline areas for radiation treatment in breast cancer patients is just as good and faster than having doctors do it by hand.

  Recruiting at 3 sites Royal North Shore Hospital · Dubbo, New South Wales and 2 other locations · NCT06546592

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.